

Veronica Mollica

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4870458/veronica-mollica-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

791
citations

16
h-index

23
g-index

115
ext. papers

1,369
ext. citations

5.9
avg, IF

5.04
L-index

#	Paper	IF	Citations
94	ECOG performance status 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data. <i>Lung Cancer</i> , 2020 , 145, 95-104	5.9	44
93	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	38
92	Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. <i>International Journal of Hyperthermia</i> , 2020 , 37, 479-485	3.7	34
91	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1329-1338	4.1	34
90	Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2020 , 16, 4409-4418	3.6	30
89	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020 , 9,	7.9	25
88	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019 , 39, 503-519	3.2	23
87	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 154, 120-127	7.5	22
86	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019 , 11,	6.6	21
85	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 631-643	3.8	21
84	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019 , 11,	6.6	20
83	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019 , 8,	7.9	20
82	Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e339-e344	3.3	18
81	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e871-e877	3.3	18
80	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2021 ,	5.1	17
79	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019 , 11, 1507-1521	3.8	15
78	The functioning side of the pancreas: a review on insulinomas. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 139-148	5.2	13

77	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 32-40	3.3	12
76	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021 ,	5.1	12
75	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. <i>Cancers</i> , 2021 , 13,	6.6	12
74	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	7	11
73	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e84-e91	3.3	11
72	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
71	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e83-e90	3.3	10
70	Specific Toxicity of Maintenance Olaparib Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2020 , 40, 597-608	2.3	9
69	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 141-150	3.8	9
68	The (Eternal) Debate on Microwave Ablation Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. <i>In Vivo</i> , 2020 , 34, 3421-3429	2.3	8
67	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
66	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
65	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020 , 34, 1701-1714	2.3	7
64	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020 , 40, 211-226	3.2	7
63	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 755-763	3.5	7
62	Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1506-1520	2.3	7
61	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 491-501	3.5	6
60	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 569-577	4.5	6

59	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020 , 7,	4.1	6
58	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 257-270	3.8	6
57	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 1286	59.2	5
56	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 710-715	2.4	5
55	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
54	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	5
53	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2021 , 17, 61	5	5
52	Avelumab Maintenance for Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 2482	59.2	4
51	Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. <i>Eur Urol</i> . In press DOI: 10.1016/j.eururo.2020.04.065. <i>European Urology</i> , 2020 , 78, e205-e206	10.2	4
50	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 1463-1475	3.5	4
49	Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis. <i>American Journal of Clinical Pathology</i> , 2021 ,	1.9	4
48	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020 , 12, 1257-1268	3.2	4
47	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. <i>Immunotherapy</i> , 2021 , 13, 685-692	3.8	4
46	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021 , 222, 153440	3.4	4
45	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-7	2.2	4
44	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1225-1232	4.2	4
43	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 207-217	3.8	4
42	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3

41	Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 751-751	2.2	3
40	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. <i>Cancers</i> , 2021 , 13,	6.6	3
39	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. <i>Pathology Research and Practice</i> , 2021 , 219, 153350	3.4	3
38	Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncol</i> . In press. https://doi.org/10.1001/jamaoncol.2020.2218 : SAVOIR: From Own Goal to Winning Goal? <i>European Urology Oncology</i> , 2020 , 3, 541-562	6.7	2
37	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.. <i>Future Oncology</i> , 2022 ,	3.6	2
36	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1541-1552	2.3	2
35	Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021 , 17, 2671-2681	3.6	2
34	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2018 , 29, 911-913	2.4	2
33	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
32	Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>N Engl J Med</i> 2021;384:1125-35. <i>European Urology Oncology</i> , 2021 , 4, 670	6.7	2
31	Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 385, 956	59.2	2
30	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. <i>European Urology Focus</i> , 2022 ,	5.1	2
29	Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations. <i>European Urology</i> , 2020 , 78, 768-770	10.2	1
28	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <i>European Urology Oncology</i> , 2019 , 2, 603-604	6.7	1
27	The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?. <i>Immunotherapy</i> , 2022 ,	3.8	1
26	Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. <i>N Engl J Med</i> . In press. https://doi.org/10.1056/NEJMoa2022485 . <i>European Urology Oncology</i> , 2020 , 3, 806	6.7	1
25	Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clin Cancer Res</i> . In press. https://doi.org/10.1158/1078-0432.ccr-20-2063 . <i>European Urology Oncology</i> , 2020 , 3, 804-805	6.7	1
24	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021 , 220, 153410	3.4	1

23	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. <i>Lancet Oncology, The</i> , 2021 , 22, e237	21.7	1
22	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>Lancet</i> 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A	6.7	1
21	Re: Alfonso Gñez de Liab Lista, Nick van Dijk, Guillermo de Velasco Oriá de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , 2021 , 79, e17-e19	10.2	1
20	Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 322-322	2.2	1
19	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1237-1243	5.5	1
18	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. <i>Anti-Cancer Drugs</i> , 2021 ,	2.4	1
17	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2323-2336	4	1
16	A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. <i>Pathology Research and Practice</i> , 2021 , 227, 153637	3.4	1
15	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. <i>Medicines (Basel, Switzerland)</i> , 2021 , 8,	4.1	1
14	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.. <i>Current Oncology</i> , 2022 , 29, 1709-1722	2.8	1
13	Current androgen receptor antagonists under investigation for resistant prostate cancer.. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-12	3.5	1
12	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. <i>Anti-Cancer Drugs</i> , 2021 , 32, 74-81	2.4	0
11	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 783-793	3.8	0
10	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1581-1587	2.3	0
9	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022 , 29, 3499-3518	3.8	0
8	The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022 , 12, 842	3.6	0
7	Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.04.038 : Cytoreductive Nephrectomy: To Whom and When?. <i>European Urology Oncology</i> , 2020 , 3, 559-560	6.7	
6	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 572-572	2.2	

- 5 Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials.. *Journal of Clinical Oncology*, **2021**, 39, e16534-e16534 2.2
- 4 Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. *JAMA Oncology*, **2021**, 7, 1068 13.4
- 3 Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity. *JAMA Oncology*, **2021**, 7, 1577 13.4
- 2 Re: Thomas Powles, Tibor Csözi, Mustafa Ögüt, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. *Lancet Oncol*. In press. [https://doi.org/10.1016/S1470-2045\(21\)00152-2](https://doi.org/10.1016/S1470-2045(21)00152-2): The Conflict of Adding Immunotherapy to 6.7
- 1 Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis.. *Tumori*, **2022**, 3008916221090323 1.7